Zh. E. Sabelnikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zh. E. Sabelnikova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Ya. Mozerova
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University
6 shared publications - Marina M. Sarycheva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University
5 shared publications - A. A. Lozhkov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
4 shared publications - Andrey V. Vazhenin
South Ural State Medical University
4 shared publications - R. Yu. Karabut
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
2 shared publications A. A. Lozhkov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
1 shared publication
Latest Publications
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 43-47
Comparative analysis of treatment options for stage T1–2N 0M0 non-small cell lung cancer
Background. The standard treatment for localized non-small cell lung cancer (NSCLC) is surgery. However, for inoperable patients or patients who refuse surgical treatment, radiation therapy in different fractionation regimens remains an alternative to surgery. Traditional radiation therapy does not provide treatment results similar to those after surgical treatment, but the use of stereotactic body radiation therapy (SBRT) changes this paradigm, allowing results comparable to surgical treatment. Purpose. To compare the results of treatment of patients with T1–2N 0M0 stages of NSCLC depending on the treatment performed – surgery, radiation therapy in the traditional fractionation mode, stereotactic radiation therapy, combined treatment. Materials and methods. From 2015 to 2021 on the basis of the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, 195 patients with non-small cell lung cancer stages T1–2N 0M0 were treated. 79 patients underwent surgical treatment, 81 patients underwent radiation therapy, and the combined treatment group included 35 patients. The operation was more often performed as a lobectomy (62 people), atypical resection was performed in 17 cases. Traditional radiation therapy was performed in 66 patients, stereotactic radiation therapy in 15 patients. In the combination treatment group, radiotherapy was given after atypical resection. Results. Overall survival (OS), regardless of treatment option, was 102 months. OS rates were high in the surgical and combined treatment groups, while median OS was not reached in the surgery group. In the radiation therapy group, OS was 54 months. Progression-free survival (PFS) was 83 months among all patients. PFS rates are highest with surgical treatment (1-year PFS 96 %), in the radiation therapy group the 1-year PFS was 78 %, in the combined treatment group – 80 %. There was no significant difference in OS and PFS depending on the histological subtype of the tumor. The 1-year OS rates in the radiation therapy (RT) group were comparable: after a radical course of RT in the traditional fractionation regimen – 90 %, after SBRT – 93 %. The 5-year OS rates were significantly different: 41 and 60 %, respectively. In a subgroup analysis of surgical treatment, there was a trend towards increased OS in the atypical resection group compared with lobectomy patients: 5-year OS was 80 and 77 %, respectively. Conclusions. Surgical treatment of stages T1–2N 0M0 non-small cell lung cancer should be the main treatment method. For inoperable patients who refuse surgical treatment, SBRT should be preferred to traditional RT.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 43-47
Comparative analysis of treatment options for stage T1–2N 0M0 non-small cell lung cancer
Background. The standard treatment for localized non-small cell lung cancer (NSCLC) is surgery. However, for inoperable patients or patients who refuse surgical treatment, radiation therapy in different fractionation regimens remains an alternative to surgery. Traditional radiation therapy does not provide treatment results similar to those after surgical treatment, but the use of stereotactic body radiation therapy (SBRT) changes this paradigm, allowing results comparable to surgical treatment. Purpose. To compare the results of treatment of patients with T1–2N 0M0 stages of NSCLC depending on the treatment performed – surgery, radiation therapy in the traditional fractionation mode, stereotactic radiation therapy, combined treatment. Materials and methods. From 2015 to 2021 on the basis of the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, 195 patients with non-small cell lung cancer stages T1–2N 0M0 were treated. 79 patients underwent surgical treatment, 81 patients underwent radiation therapy, and the combined treatment group included 35 patients. The operation was more often performed as a lobectomy (62 people), atypical resection was performed in 17 cases. Traditional radiation therapy was performed in 66 patients, stereotactic radiation therapy in 15 patients. In the combination treatment group, radiotherapy was given after atypical resection. Results. Overall survival (OS), regardless of treatment option, was 102 months. OS rates were high in the surgical and combined treatment groups, while median OS was not reached in the surgery group. In the radiation therapy group, OS was 54 months. Progression-free survival (PFS) was 83 months among all patients. PFS rates are highest with surgical treatment (1-year PFS 96 %), in the radiation therapy group the 1-year PFS was 78 %, in the combined treatment group – 80 %. There was no significant difference in OS and PFS depending on the histological subtype of the tumor. The 1-year OS rates in the radiation therapy (RT) group were comparable: after a radical course of RT in the traditional fractionation regimen – 90 %, after SBRT – 93 %. The 5-year OS rates were significantly different: 41 and 60 %, respectively. In a subgroup analysis of surgical treatment, there was a trend towards increased OS in the atypical resection group compared with lobectomy patients: 5-year OS was 80 and 77 %, respectively. Conclusions. Surgical treatment of stages T1–2N 0M0 non-small cell lung cancer should be the main treatment method. For inoperable patients who refuse surgical treatment, SBRT should be preferred to traditional RT.
- Open Access
- 24 May 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 44-50
Comparative analysis of the results of surgical and radiation treatment of stage I kidney cancer
Purpose of the study: To conduct a comparative assessment of the results of surgical and radiation treatment of patients with stage I renal cell carcinoma (RCC) in terms of overall survival (OS), progression-free survival (PFS), local control and changes in renal function. Material and methods: From 2011 to 2022 170 patients with stage I RCC were treated at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. We conducted a retrospective study of their treatment results. The first group — 115 patients who underwent surgical treatment of T1N0M0 kidney cancer (mainly in the amount of kidney resection — 85 people), the second group — 55 patients with verified T1N0M0 renal cell carcinoma who underwent stereotactic radiation therapy (SBRT) up to 30–45 Gy in 3 fractions using CyberKnife. SBRT was performed mainly for the treatment of a primary kidney tumor, in 7 cases — for a recurrence of kidney cancer, including 1 patient with recurrent tumors in both kidneys. The average age of patients in the surgery group was 73 years, in the SBRT group — 69.9 years. The average tumor diameter in the operation group was 4.3 cm, in the SBRT group it was 3.5 cm. Results: The median OS in the surgery group was 121 months, but it was not achieved in the SBRT group, since most patients are alive at the time of the study. 1‑year OS in the surgery group and SBRT was comparable (98.9 % and 95.1 %, respectively), but 5‑year OS in the surgery group was significantly higher — 90.2 % vs. 70 % in the SBRT group (p < 0.05). The same trend was noted in the assessment of PFS. In the surgery group, 4 patients out of 115 (3.5 %) had a recurrence in the tumor bed, in all cases after kidney resection, after 28 months in average. In the SBRT group, 42 patients (75 %) according to RECIST 1.1 criteria 6 months after SBRT showed stabilization of the process, in 20 % of cases (11 patients) — a partial response, in 5 % (3 patients) — progressed disease. 1‑year local control was 96.4 %, 1‑year cancer‑specific survival in both groups was 100 %. Renal toxicity was recorded in 38 patients (33 %) in the surgery group and in 10 patients (18 %) in the radiotherapy group 6 months after treatment. On average, glomerular filtration rate decreased by 25 % in the surgery group and by 18 % in the radiotherapy group. We have not noted a single case of a pronounced decrease in GFR, which would require dialysis. Conclusion: Surgery remains the main treatment option for T1N0M0 kidney cancer, but if there are contraindications to surgery, SBRT may be the best option for inoperable patients.
- 24 May 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 44-50
Open AccessComparative analysis of the results of surgical and radiation treatment of stage I kidney cancer
Purpose of the study: To conduct a comparative assessment of the results of surgical and radiation treatment of patients with stage I renal cell carcinoma (RCC) in terms of overall survival (OS), progression-free survival (PFS), local control and changes in renal function. Material and methods: From 2011 to 2022 170 patients with stage I RCC were treated at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. We conducted a retrospective study of their treatment results. The first group — 115 patients who underwent surgical treatment of T1N0M0 kidney cancer (mainly in the amount of kidney resection — 85 people), the second group — 55 patients with verified T1N0M0 renal cell carcinoma who underwent stereotactic radiation therapy (SBRT) up to 30–45 Gy in 3 fractions using CyberKnife. SBRT was performed mainly for the treatment of a primary kidney tumor, in 7 cases — for a recurrence of kidney cancer, including 1 patient with recurrent tumors in both kidneys. The average age of patients in the surgery group was 73 years, in the SBRT group — 69.9 years. The average tumor diameter in the operation group was 4.3 cm, in the SBRT group it was 3.5 cm. Results: The median OS in the surgery group was 121 months, but it was not achieved in the SBRT group, since most patients are alive at the time of the study. 1‑year OS in the surgery group and SBRT was comparable (98.9 % and 95.1 %, respectively), but 5‑year OS in the surgery group was significantly higher — 90.2 % vs. 70 % in the SBRT group (p < 0.05). The same trend was noted in the assessment of PFS. In the surgery group, 4 patients out of 115 (3.5 %) had a recurrence in the tumor bed, in all cases after kidney resection, after 28 months in average. In the SBRT group, 42 patients (75 %) according to RECIST 1.1 criteria 6 months after SBRT showed stabilization of the process, in 20 % of cases (11 patients) — a partial response, in 5 % (3 patients) — progressed disease. 1‑year local control was 96.4 %, 1‑year cancer‑specific survival in both groups was 100 %. Renal toxicity was recorded in 38 patients (33 %) in the surgery group and in 10 patients (18 %) in the radiotherapy group 6 months after treatment. On average, glomerular filtration rate decreased by 25 % in the surgery group and by 18 % in the radiotherapy group. We have not noted a single case of a pronounced decrease in GFR, which would require dialysis. Conclusion: Surgery remains the main treatment option for T1N0M0 kidney cancer, but if there are contraindications to surgery, SBRT may be the best option for inoperable patients.
- 5 December 2023
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 51-55
Results of stereotactic radiation therapy in treatment of patients with T1N0M0 kidney cancer
Background. Currently, the main treatment for T1N0M0 kidney cancer is surgery, mainly in the amount of kidney resection. However, not all patients can be operated on, and most often due to the severity of comorbidity, some patients refuse surgery. In such cases, it becomes necessary to search for an acceptable operation of an alternative method of treatment. Such requirements can be met by stereotactic radiotherapy (SBRT), being a non-invasive method of treating renal cell carcinoma.Purpose. To determine overall survival (OS), local control, and renal toxicity after treatment of T1N0M0 renal cell carcinoma (RCC) with stereotactic radiotherapy.Material and methods. Since 2011 to 2022 in the Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine, 50 patients with verified RCC underwent SBRT up to 30–45 Grey in three fractions using the CyberKnife. The mean age of the patients was 69.8 years. Primary tumor was diagnosed in 44 cases, recurrence after previous surgical treatment in 6 cases, including one patient with recurrence of cancer of both kidneys. The average tumor volume was 29.1 cm3 .Results. Median overall survival was not reached as most patients were alive at the time of the study. Indicators of 1-, 3- and 5-year OS are 94.8%, 87.3% and 75.1%, respectively. In 74.5% of cases, according to the RECIST 1.1 criteria, stabilization of the process was recorded 6 months after STLT, in 21.6% of cases – a partial response, in 3.9% – progression of the process. One-year local control – 98%. Renal toxicity occurred in 26% of patients 6 months after radiation therapy, but within a year, kidney function was restored in these patients.Conclusions. Stereotactic radiation therapy T1N0M0 of kidney cancer in SOD = 30–45 Grey allows to stabilize the tumor process with sufficiently high results of overall survival and local control with low renal toxicity, respectively, can be used in the treatment of inoperable patients with localized renal cell carcinoma.
- 5 December 2023
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 51-55
Results of stereotactic radiation therapy in treatment of patients with T1N0M0 kidney cancer
Background. Currently, the main treatment for T1N0M0 kidney cancer is surgery, mainly in the amount of kidney resection. However, not all patients can be operated on, and most often due to the severity of comorbidity, some patients refuse surgery. In such cases, it becomes necessary to search for an acceptable operation of an alternative method of treatment. Such requirements can be met by stereotactic radiotherapy (SBRT), being a non-invasive method of treating renal cell carcinoma.Purpose. To determine overall survival (OS), local control, and renal toxicity after treatment of T1N0M0 renal cell carcinoma (RCC) with stereotactic radiotherapy.Material and methods. Since 2011 to 2022 in the Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine, 50 patients with verified RCC underwent SBRT up to 30–45 Grey in three fractions using the CyberKnife. The mean age of the patients was 69.8 years. Primary tumor was diagnosed in 44 cases, recurrence after previous surgical treatment in 6 cases, including one patient with recurrence of cancer of both kidneys. The average tumor volume was 29.1 cm3 .Results. Median overall survival was not reached as most patients were alive at the time of the study. Indicators of 1-, 3- and 5-year OS are 94.8%, 87.3% and 75.1%, respectively. In 74.5% of cases, according to the RECIST 1.1 criteria, stabilization of the process was recorded 6 months after STLT, in 21.6% of cases – a partial response, in 3.9% – progression of the process. One-year local control – 98%. Renal toxicity occurred in 26% of patients 6 months after radiation therapy, but within a year, kidney function was restored in these patients.Conclusions. Stereotactic radiation therapy T1N0M0 of kidney cancer in SOD = 30–45 Grey allows to stabilize the tumor process with sufficiently high results of overall survival and local control with low renal toxicity, respectively, can be used in the treatment of inoperable patients with localized renal cell carcinoma.
- Open Access
- 3 May 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (2) , 120-128
Stereotactic body radiation therapy for inoperable localized kidney cancer
Purpose of the study: to evaluate the overall survival and local control in patients with inoperable kidney cancer treated with stereotactic body radiotherapy (SBRT). Material and Methods. From 2011 to 2021, 42 patients with histologically verified kidney cancer underwent SBRT to a total dose ranging from 30 to 45 Gr in 3 fractions using the CyberKnife robotic radiosurgical system. SBRT was performed for inoperable patients, taking into account various factors (age, severity of concomitant pathology, ASA IV physical status level), patients’ refusal of surgical treatment, and tumor size of ≤5.0 cm in diameter. SBRT was not performed for patients with tumor size of ≥5.0 cm in diameter, impaired renal function, generalization of cancer and decompensation of concomitant pathology. The median age of the patients was 67.9 years. 93 % of patients had stage I kidney cancer. The primary tumor was diagnosed in 37 cases, recurrence after previous surgical treatment in 6, including 1 patient with recurrence of cancer of both kidneys. The average tumor volume was 28.1 cm3. Results. The median overall survival (OS) was not reached due to the fact that the majority of patients (n=36) were alive at the time of the study. The 1-, 3- and 5-year OS rates were 94.1 %, 88.7 %, and 72.6 %, respectively. The 1-year local control rate was 93 %. At 3-6 months, 26.2 % of patients showed partial response, 66.8 % had stable disease and 7 % had disease progression (according to the RECIST 1.1 criteria). Renal toxicity occurred in 23.8 % of patients 3 months after radiation therapy; however, kidney function was restored in these patients within a year. Conclusion. SBRT has demonstrated high efficacy with minimal toxicity in the treatment of inoperable patients with kidney cancer.
- 3 May 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (2) , 120-128
Open AccessStereotactic body radiation therapy for inoperable localized kidney cancer
Purpose of the study: to evaluate the overall survival and local control in patients with inoperable kidney cancer treated with stereotactic body radiotherapy (SBRT). Material and Methods. From 2011 to 2021, 42 patients with histologically verified kidney cancer underwent SBRT to a total dose ranging from 30 to 45 Gr in 3 fractions using the CyberKnife robotic radiosurgical system. SBRT was performed for inoperable patients, taking into account various factors (age, severity of concomitant pathology, ASA IV physical status level), patients’ refusal of surgical treatment, and tumor size of ≤5.0 cm in diameter. SBRT was not performed for patients with tumor size of ≥5.0 cm in diameter, impaired renal function, generalization of cancer and decompensation of concomitant pathology. The median age of the patients was 67.9 years. 93 % of patients had stage I kidney cancer. The primary tumor was diagnosed in 37 cases, recurrence after previous surgical treatment in 6, including 1 patient with recurrence of cancer of both kidneys. The average tumor volume was 28.1 cm3. Results. The median overall survival (OS) was not reached due to the fact that the majority of patients (n=36) were alive at the time of the study. The 1-, 3- and 5-year OS rates were 94.1 %, 88.7 %, and 72.6 %, respectively. The 1-year local control rate was 93 %. At 3-6 months, 26.2 % of patients showed partial response, 66.8 % had stable disease and 7 % had disease progression (according to the RECIST 1.1 criteria). Renal toxicity occurred in 23.8 % of patients 3 months after radiation therapy; however, kidney function was restored in these patients within a year. Conclusion. SBRT has demonstrated high efficacy with minimal toxicity in the treatment of inoperable patients with kidney cancer.
- 7 December 2021
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (31) , 31-33
Results of salvage radiotherapy for prostate cancer after radical prostatectomy
The aim of the study. To evaluate the results of radiation therapy for recurrent prostate cancer after radical prostatectomy.Methods. The analysis of medical records data of 60 patients with recurrent prostate cancer after radical prostatectomy (RP) was performed.Results. Biochemical control was achieved in 55 (92.0%) patients, PSA progression – in 3 (5.0%) and generalization – in 2 (3.0%) patients. Grade I–II cystitis developed in 25 patients (42.0%), grade I–II rectitis – in 7 (11.0%), late hemorrhagic cystitis was noted in 4 (7.0%) patients, late hemorrhagic rectitis – in 2 (3.3%) ones.Сonclusions. Salvage radiation therapy for recurrent prostate cancer after radical prostatectomy is an important treatment method that allows to achieve biochemical control with acceptable toxicity.
- 7 December 2021
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (31) , 31-33
Results of salvage radiotherapy for prostate cancer after radical prostatectomy
The aim of the study. To evaluate the results of radiation therapy for recurrent prostate cancer after radical prostatectomy.Methods. The analysis of medical records data of 60 patients with recurrent prostate cancer after radical prostatectomy (RP) was performed.Results. Biochemical control was achieved in 55 (92.0%) patients, PSA progression – in 3 (5.0%) and generalization – in 2 (3.0%) patients. Grade I–II cystitis developed in 25 patients (42.0%), grade I–II rectitis – in 7 (11.0%), late hemorrhagic cystitis was noted in 4 (7.0%) patients, late hemorrhagic rectitis – in 2 (3.3%) ones.Сonclusions. Salvage radiation therapy for recurrent prostate cancer after radical prostatectomy is an important treatment method that allows to achieve biochemical control with acceptable toxicity.
- Open Access
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 77-84
NEUTRON RADIATION THERAPY IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMA
НЕЙТРОННАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ЛЕЧЕНИИ РЕЦИДИВОВ ВЫСОКОЗЛОКАЧЕСТВЕННЫХ ГЛИОМ ГОЛОВНОГО МОЗГА
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 77-84
Open AccessNEUTRON RADIATION THERAPY IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMA
НЕЙТРОННАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ЛЕЧЕНИИ РЕЦИДИВОВ ВЫСОКОЗЛОКАЧЕСТВЕННЫХ ГЛИОМ ГОЛОВНОГО МОЗГА